Archives

Perfusfind S.L.

Abstract Cardiogenic shock (CS) remains a high-mortality condition that demands rapid diagnosis, coordinated multidisciplinary management, and timely initiation of mechanical circulatory support. As more institutions implement dedicated CS teams, substantial..

Perfusfind S.L.

Abstract Context: Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is a life-sustaining therapy for severe refractory cardiogenic shock. Although VA-ECMO provides various degrees of cardiopulmonary support, mortality rates remain high. Serum biomarkers have..

Perfusfind S.L.

Abstract Managing refractory cardiogenic shock is individualized, with few aspects considered routine or universally contraindicated. Venoarterial extracorporeal membrane oxygenation (VA-ECMO) is a temporary mechanical circulatory support strategy, providing hemodynamic stabilization..

Perfusfind S.L.

Abstract Dear Editor, The timely liberation of cardiogenic shock (CS) patients from veno-arterial extracorporeal membrane oxygenation (V-A ECMO) is crucial to reduce device  complications, although the predictor of weaning is..

Perfusfind S.L.

Abstract Importance  Levosimendan may facilitate weaning from venoarterial extracorporeal membrane oxygenation (VA-ECMO) and improve survival, but supporting evidence remains limited. Objective  To assess whether early administration of levosimendan reduces the time to..

Perfusfind S.L.

Abstract Background For decades, the intra-aortic balloon pump (IABP) has been a reliable and readily available pillar of therapy for cardiogenic shock (CS). However, no clinical markers have been validated..

Perfusfind S.L.

Abstract Background Immediate initiation of extracorporeal membrane oxygenation (ECMO) has not demonstrated benefit in individuals diagnosed with cardiogenic shock based on the presence of hypotension. The relationship between other hemodynamic..

Perfusfind S.L.

Abstract Objective To construct a nomogram prediction model for death in patients with cardiogenic shock after extracorporeal membrane oxygenation (ECMO) weaning. Methods Totally 210 patients with cardiogenic shock treated with..

Perfusfind S.L.

Abstract Background: The use of temporary mechanical circulatory support (tMCS) has revolutionized the management of cardiogenic shock (CS). However, standardized readiness-to-explant criteria for venoarterial extracorporeal membrane oxygenation (VA-ECMO) have not been..

Perfusfind S.L.

Abstract Background/Objectives: Mechanical circulatory support (MCS) is increasingly utilized for the management of acute decompensated heart failure (HF) and cardiogenic shock (CS). The primary goals of MCS are to restore systemic..

Perfusfind S.L.

Abstract Background Active mechanical circulatory support (MCS) is associated with high complication rates. Reducing device-related complications may improve outcomes in patients with infarct-related cardiogenic shock (AMI-CS). This study aims to..

Perfusfind S.L.

Abstract The 2025 European Resuscitation Council (ERC) Guidelines present the most up-to-date evidence-based guidelines for the practice of resuscitation across Europe. The ERC Guidelines 2025 are based on evidence produced..

Perfusfind S.L.

Abstract Background The experience of a percutaneous microaxial (Impella)  in children with  is limited. The primary objective of this study was to review our institutional clinical outcomes of Impella use in children..

Perfusfind S.L.

Abstract Background The identification, triage, and management of cardiogenic shock (CS) are complex and resource intensive, particularly given the recent surge in the use of temporary mechanical circulatory support (tMCS)..

Perfusfind S.L.

Abstract Abstract Objectives:  To investigate whether severe hyperoxia predisposes to end-organ complications and whether these complications contribute to in-hospital mortality among cardiogenic shock (CS) patients supported in veno-arterial extracorporeal membrane..

Perfusfind S.L.

Abstract Cardiogenic shock (CS) is a state of critical end-organ hypoperfusion caused by primary cardiac failure, in which the heart cannot generate sufficient output despite adequate preload and is associated..

Perfusfind S.L.

Venoarterial extracorporeal membrane oxygenation (VA ECMO) provides temporary mechanical circulatory support for patients in refractory cardiogenic shock. Initiation of VA ECMO often results in increased left ventricular (LV) afterload as..

Perfusfind S.L.

Abstract Background Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) use for cardiogenic shock (CS) is increasing worldwide despite conflicting results from randomized trials, which focused on myocardial-infarction related CS (MI-CS). Methods We..

Perfusfind S.L.

Abstract Background Mixed cardiogenic and septic shock has been shown to have a higher mortality than cardiogenic shock alone and presents a unique hemodynamic phenotype. Objectives This study aimed to..

Perfusfind S.L.

Abstract Post cardiac surgery shock (PCS) is a life-threatening condition that may require the use of mechanical circulatory support. Venoarterial (VA) extracorporeal membrane oxygenation (ECMO) is increasingly used to treat..

Perfusfind S.L.

Abstract Objectives To describe outcomes in patients who received venoarterial extracorporeal membrane oxygenation (VA-ECMO) for cardiogenic shock and to evaluate outcomes following programmatic changes. Design A retrospective cohort study. Setting..

Perfusfind S.L.

Abstract OBJECTIVES Cardiogenic shock is still a major clinical challenge, despite the available devices. We developed a minimally invasive, transapical dual-lumened cannula, which can provide antegrade circulatory support and unloading..

Perfusfind S.L.

Abstract Background: Severe poisoning can lead to catastrophic cardiovascular collapse, often progressing to multiorgan failure and death. While intensive supportive care and pharmacological intervention remain the cornerstone of management, cases of..

Perfusfind S.L.

Abstract Extracorporeal membrane oxygenation (ECMO) is widely recognized as a life-saving measure. The use of veno-arterial extracorporeal membrane oxygenation (VA ECMO) is on the rise, serving as an effective mechanical..

Perfusfind S.L.

Abstract Background A systemic inflammatory response can contribute to poor outcomes in an advanced stage of cardiogenic shock (CS). We investigated the efficacy of extracorporeal endotoxin and cytokine adsorption using..

Perfusfind S.L.

Abstract Background A systemic inflammatory response can contribute to poor outcomes in an advanced stage of cardiogenic shock (CS). We investigated the efficacy of extracorporeal endotoxin and cytokine adsorption using..

Perfusfind S.L.

Abstract Introduction Extracorporeal membrane oxygenation (ECMO) is an established therapy that supports a patient in respiratory or cardiopulmonary failure to recovery, transplant, or durable mechanical support. Prompt referral by the..

Perfusfind S.L.

Abstract Background Immediate initiation of extracorporeal membrane oxygenation (ECMO) has not demonstrated benefit in individuals diagnosed with cardiogenic shock based on the presence of hypotension. The relationship between other hemodynamic..

Perfusfind S.L.

Abstract Background The microaxial flow pump (mAFP) improves survival in selected patients with ST-segment elevation myocardial infarction–induced cardiogenic shock (STEMI-CS). Understanding the impact on cardiac output (CO), cardiac power output..

Perfusfind S.L.

Abstract We investigated echocardiographic and hemodynamic effects of intraaortic balloon pump (IABP) in 26 patients with cardiogenic shock on veno-arterial membrane oxygenation (VA ECMO). Our study demonstrated an 8.1% increase..